Maggie Hassan (D-NH)

Medication Competition Act

S. 4332 · Senate bill Health

A Democratic bill with 1 Republican cosponsor · See the cosponsor

Last activity — Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

In committee

Introduced and handed to a committee in the chamber it started in.

The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.

Its path through Congress

  1. Introduced
  2. In Committee

What this bill would do

The Medication Competition Act requires the Secretary of Health and Human Services to determine exclusivity periods for licensed biological products. It amends the Public Health Service Act to include specific requirements for listing these periods. The bill establishes different timelines for products licensed before or after the date of enactment. Specifically, it mandates how the Secretary must publish exclusivity periods for both first interchangeable biological products and reference products. This ensures that the Secretary includes expiration dates on published lists within specific timeframes.

Yes· 3 of 5

  • Scored +4

    Does this make what the government does easier for the public to see?

    The bill mandates specific timelines for the Secretary of Health and Human Services to publish expiration dates for biological product exclusivity.

  • Scored +3

    Does this give people more protection from unfair business practices?

    The bill increases transparency regarding biological product exclusivity periods, which can assist in market competition and consumer awareness.

  • Scored +2

    Would households on low incomes be better off under this?

    Increased transparency in biological product exclusivity can lead to greater market competition and lower drug costs for consumers.

The opposite

No question was scored the opposite.